ストックスクリーナーアプリを入手
2.10
0.94%
-0.02
アフターアワーズ：
2.10
前日終値:
$2.12
開ける：
$2.12
24時間の取引高:
181.91K
Relative Volume:
0.47
時価総額：
$89.99M
収益：
-
当期純損益:
$-77.27M
株価収益率:
-1.049
EPS:
-2.0019
ネットキャッシュフロー:
$-66.29M
1週間 パフォーマンス:
+13.51%
1か月 パフォーマンス:
-3.67%
6か月 パフォーマンス:
+38.16%
1年 パフォーマンス:
+36.36%
1日の値動き範囲:
$2.07
$2.13
1週間の範囲:
$1.8706
$2.24
52週間の値動き範囲:
$1.27
$3.56
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
名前
Acrivon Therapeutics Inc
セクター
電話
617-207-8979
住所
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
2.10 | 89.99M | 0 | -77.27M | -66.29M | -2.0019 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-05 | 再開されました | Piper Sandler | Overweight |
| 2025-01-31 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | アップグレード | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-12-15 | 再開されました | Jefferies | Buy |
| 2023-10-05 | 開始されました | Maxim Group | Buy |
| 2023-06-02 | 開始されました | Oppenheimer | Outperform |
| 2023-05-08 | 開始されました | BMO Capital Markets | Outperform |
| 2023-04-27 | 開始されました | Ladenburg Thalmann | Buy |
| 2023-04-20 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-12 | 開始されました | Cowen | Outperform |
| 2022-12-12 | 開始されました | Jefferies | Buy |
| 2022-12-12 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Acrivon Therapeutics Inc (ACRV) 最新ニュース
Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock - simplywall.st
What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock - Yahoo Finance
Acrivon Therapeutics, Inc. (ACRV) Earnings Date, Reports and Estimates - Traders Union
ACRIVON THERAPEUTICS INC (ACRV) Stock Price & Overview - ChartMill
Acrivon Therapeutics at 12th annual Cantor Fitzgerald conference: platform push - Investing.com Canada
Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy? - Yahoo Finance
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference - The Manila Times
Acrivon Therapeutics files Form 3 for Chief Business Officer Michaela Levin - Bitget
acrivon appoints michaela levin as chief business officer By Investing.com - Investing.com Nigeria
Acrivon Therapeutics Names Michaela Levin Chief Business Officer - citybiz
acrivon appoints michaela levin as chief business officer - investing.com
Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer - GlobeNewswire
ACRV Q2 2026 Earnings: Narrower-Than-Expected Loss in a Pre-Revenue QuarterProfit Margin Analysis - vinanet.vn
Acrivon (NASDAQ: ACRV) CEO sells 14K shares to cover RSU taxes - Stock Titan
Acrivon (ACRV) Results Breakdown: EPS Lands Above Forecast in Latest Trading; Share Response: The Stock Records a 0.91% Decrease in the Current UpdatePost-Earnings Reaction - dars.gov.et
Acrivon (NASDAQ: ACRV) CEO may sell stock from vested RSUs - stocktitan.net
Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy - Yahoo Finance
Acrivon Therapeutics (ACRV) CLO sells 185 shares for taxes - Stock Titan
Acrivon Therapeutics (ACRV) insider offloads 400 shares for taxes - Stock Titan
Acrivon Therapeutics (ACRV) COO’s tax sale leaves 146,349 shares - Stock Titan
Acrivon (NASDAQ: ACRV) chiefs sell shares to cover RSU taxes - Stock Titan
Acrivon (ACRV) Results Breakdown: EPS Exceeds Its Estimate in the Latest Session; Post-Report: The Stock Closes Near Unchanged on the DayFull Year Guidance - vinanet.vn
ACRV Q1 2026 Earnings: Narrower-than-Expected Loss Lifts Shares 5.9%Capex Guidance - vinanet.vn
Acrivon Therapeutics Inc (ACRV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Q3 EPS Estimate for Acrivon Therapeutics Raised by Analyst - MarketBeat
ACRV Q1 2026 Earnings: Loss Narrower Than Expected, Stock Advances 5.41%Forward EPS Estimate - Vinanet
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings - MarketBeat
Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Sands Capital group (NASDAQ: ACRV) discloses 5.3% Acrivon ownership in 13G/A - Stock Titan
Acrivon Therapeutics: Buy Rating Reaffirmed as Pipeline Progress Supports Attractive Valuation; $19 Price Target Maintained - TipRanks
Acrivon Therapeutics, Inc. (ACRV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Acrivon Therapeutics Q2 2026: Net loss narrows to $18.0M, cash at $90.0M - scanx.trade
Acrivon Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Acrivon Therapeutics (NASDAQ:ACRV) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Acrivon Therapeutics (ACRV) Slips to $1.72, Holds Support at $1.63Imbalance Zone - Vinanet
Acrivon Therapeutics Q2 net loss narrows as costs decline - TradingView
BRIEF-Acrivon Therapeutics, Inc Q2 Income From Operations USD -18.668 Million - TradingView
Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts - GlobeNewswire
Acrivon Therapeutics Inc (ACRV) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Acrivon Therapeutics, Inc. expected to post a loss of 50 cents a shareEarnings Preview - TradingView
Acrivon Therapeutics Inc (ACRV) Stock News Today - TradingKey
(ACRV) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Acrivon Therapeutics, Inc. (ACRV) CFO sells 1,142 shares to cover taxes - Stock Titan
Acrivon Therapeutics: Buy Rating Reiterated as ACR-2316’s Emerging Clinical Profile and Differentiated Safety Support Unchanged $19 Price Target - TipRanks
Acrivon advances cancer drug ACR-2316 to dose expansion phase By Investing.com - Investing.com Nigeria
Acrivon advances cancer drug ACR-2316 to dose expansion phase - Investing.com
Acrivon Therapeutics (ACRV) Projected to Post Earnings on Wednesday - MarketBeat
Acrivon Advances ACR-2316, a Potential First-in-Class - GlobeNewswire
Acrivon Therapeutics (ACRV) Holds Near Support as Shares Edge Higher in Quiet SessionETF Creation Redemption - vinanet.vn
ACRV|Acrivon Therapeutics Inc|Price:1.550|Chg%:+0.050 - TradingKey
Acrivon Therapeutics Inc (ACRV) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):